

2012 BIOTECHNOLOGY RESEARCH REVIEW



BIO069D
December 2012

Various Analysts
Project Analyst

ISBN: 0-89336-180-1

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports: carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 2012 BIOTECHNOLOGY RESEARCH REVIEW	1
FOREWORD	1
CHAPTER 2 AGRICULTURAL BIOTECHNOLOGY: EMERGING TECHNOLOGIES AND GLOBAL MARKETS (REPORT BIO100A)	3
STUDY GOALS AND OBJECTIVES	3
REASONS FOR DOING THE STUDY	3
CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE	3
SCOPE AND FORMAT	4
METHODOLOGY	4
INFORMATION SOURCES	4
RELATED BCC REPORTS	5
ANALYST CREDENTIALS	5
BCC ONLINE SERVICES	5
DISCLAIMER	5
<i>TABLE 1 GLOBAL VALUE OF AGRICULTURAL BIOTECHNOLOGY MARKET, BY MARKET SEGMENT, THROUGH 2017 (\$ MILLIONS)</i>	6
<i>FIGURE 1 GLOBAL VALUE OF AGRICULTURAL BIOTECHNOLOGY MARKET BY MARKET SEGMENT, 2011-2017 (\$ MILLIONS)</i>	6
SCOPE OF REPORT	7
<i>TABLE 2 SCOPE OF THIS REPORT</i>	7
AGRICULTURAL BIOTECHNOLOGY MARKET	8
<i>TABLE 3 GLOBAL VALUE OF AGRICULTURAL BIOTECHNOLOGY MARKET BY MARKET SEGMENT, THROUGH 2017 (\$ MILLIONS)</i>	8
GROWTH DRIVING FORCES	9
<i>TABLE 4 AGRICULTURAL BIOTECHNOLOGY MARKET DRIVING FORCES</i>	9
LIFE CYCLE STATUS	10
<i>TABLE 5 LIFE CYCLE STATUS OF AGRICULTURAL BIOTECHNOLOGIES</i>	10
<i>TABLE 6 IMPACT OF NEW TECHNOLOGIES ON CROP PRODUCTIVITY, 1860-PRESENT</i>	11
AGRICULTURAL BIOTECHNOLOGY INDUSTRY	11
<i>TABLE 7 AGRICULTURAL BIOTECHNOLOGY INDUSTRY KEY STRUCTURAL COMPONENTS</i>	11
TECHNOLOGIES	12
DNA SEQUENCING	12
<i>TABLE 8 DNA SEQUENCING TECHNOLOGY</i>	12
<i>TABLE 9 DNA SEQUENCING TECHNOLOGY IN AGRICULTURAL BIOTECHNOLOGY</i>	13
GENETIC ENGINEERING/SYNTHETIC BIOLOGY	13
<i>TABLE 10 COMPARISON OF GENETIC ENGINEERING AND SYNTHETIC BIOLOGY</i>	14
<i>TABLE 11 GENETIC ENGINEERING/SYNTHETIC BIOLOGY TECHNOLOGY IN AGRICULTURAL BIOTECHNOLOGY</i>	15
BIOCHIPS	15
<i>TABLE 12 BIOCHIPS TECHNOLOGIES</i>	16
<i>TABLE 13 BIOCHIPS TECHNOLOGIES IN AGRICULTURAL BIOTECHNOLOGY</i>	16
RNA INTERFERENCE	17
<i>TABLE 14 RNA INTERFERENCE TECHNOLOGY</i>	17
<i>TABLE 15 RNA INTERFERENCE AGRICULTURAL TECHNOLOGIES</i>	18
CROP TECHNOLOGIES	18

TOPIC	PAGE NO.
<i>TABLE 16 PLANT TECHNOLOGIES</i>	18
Development of a Genetically Modified Seed	19
<i>TABLE 17 GENETICALLY MODIFIED SEED DEVELOPMENT PROCESS</i>	19
<i>TABLE 18 SEED PRODUCTION, STORAGE AND ENHANCEMENT TECHNOLOGIES</i>	20
CHAPTER 3 BIOSIMILARS: GLOBAL MARKETS (REPORT BIO090A)	22
STUDY GOAL AND OBJECTIVES	22
INTENDED AUDIENCE OF THE STUDY	23
MARKET DEFINITION, SCOPE AND FORMAT	23
INFORMATION SOURCES AND METHODOLOGY	24
AUTHOR CREDENTIALS	25
RELATED REPORTS FROM BCC RESEARCH	25
SUMMARY	25
<i>TABLE 19 GLOBAL DEMAND FOR BIOSIMILARS BY VALUE, THROUGH 2016 (\$ MILLIONS)</i>	26
<i>FIGURE 2 GLOBAL BIOSIMILAR DEMAND BY VALUE AND PRODUCT TYPE, 2011 (%)</i>	26
MARKET OVERVIEW	27
TERMINOLOGY	28
<i>TABLE 20 SIMILAR BIOLOGICAL PRODUCTS: TERMINOLOGIES AND THEIR DEFINITIONS AS USED BY VARIOUS REGULATORY AGENCIES</i>	29
SMALL MOLECULE GENERICS VERSUS BIOSIMILARS	30
DISTINCT INTELLECTUAL PROPERTY ISSUES	32
<i>TABLE 21 BIOSIMILARS VERSUS SMALL MOLECULE GENERICS</i>	32
THE BIOSIMILAR OPPORTUNITY	33
<i>TABLE 22 GLOBAL REVENUES OF LEADING BIOPHARMACEUTICALS</i>	34
<i>TABLE 23 BIOLOGIC DRUGS LOSING PATENT PROTECTION BETWEEN 2012 AND 2017</i>	34
<i>TABLE 24 POPULAR REFERENCE PRODUCTS TARGETED BY KEY PLAYERS</i>	35
VERY EXPENSIVE BIOLOGIC DRUGS DRIVING THE DEMAND FOR BIOSIMILARS	35
<i>TABLE 25 ANNUAL COSTS FOR THE TREATMENT USING SOME OF THE BIOLOGIC DRUGS</i>	35
<i>TABLE 26 COST COMPARISON FOR RENAL DISEASE-ASSOCIATED ANEMIA TREATMENT IN EUROPE</i>	36
WORLDWIDE MARKETS FOR BIOSIMILARS-CURRENT STATUS	36
<i>TABLE 27 BIOSIMILARS APPROVED BY EMA, 2011</i>	37
<i>TABLE 28 BIOSIMILARS APPROVED IN OTHER REGULATED MARKETS: AUSTRALIA, CANADA, JAPAN AND THE U.S.</i>	38
<i>TABLE 29 TOP PLAYERS IN THE GLOBAL BIOSIMILAR MARKET</i>	39
MARKET SIZE AND GROWTH TRENDS OF GLOBAL BIOSIMILAR MARKET	39
<i>TABLE 30 THE GLOBAL AND REGIONAL BIOSIMILAR MARKETS BY VALUE, THROUGH 2016 (\$ MILLIONS)</i>	40
<i>TABLE 31 THE GLOBAL MARKETS FOR VARIOUS PRODUCT CLASSES OF BIOSIMILARS BY VALUE, THROUGH 2016 (\$ MILLIONS)</i>	41
THE EVOLVING BIOSIMILAR REGULATORY LANDSCAPE	42
UNRESOLVED SCIENTIFIC AND REGULATORY CONCERNS	43
<i>TABLE 32 SCIENTIFIC AND REGULATORY CONCERNS RELATED TO BIOSIMILAR AUTHORIZATION</i>	43
CHAPTER 4 KINASE INHIBITORS: GLOBAL MARKETS (REPORT BIO053C)	46
STUDY OBJECTIVES	46
REASONS FOR DOING THIS STUDY	46
INTENDED AUDIENCE	46

TOPIC	PAGE NO.
SCOPE OF THE STUDY	46
METHODOLOGY	47
INFORMATION SOURCES	47
AUTHOR CREDENTIALS	47
SUMMARY	47
<i>TABLE 33 GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016 (\$ MILLIONS)</i>	49
<i>FIGURE 3 GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016 (\$ MILLIONS)</i>	49
OVERVIEW	49
DEFINITIONS	49
ENZYME INHIBITORS	50
WHY ENZYME INHIBITION?	50
USE OF ENZYME INHIBITORS	50
MECHANISM OF ENZYME INHIBITION	51
TYPES OF ENZYME INHIBITORS	51
CLASSIFICATION OF ENZYME INHIBITORS	52
<i>TABLE 34 CLASSIFICATION OF ENZYME INHIBITORS</i>	52
KINASE INHIBITORS	53
HISTORY OF PROTEIN KINASES	54
<i>TABLE 35 HISTORY OF PROTEIN KINASES</i>	54
TYPES OF KINASE INHIBITORS	55
<i>TABLE 36 TYPES OF KINASE INHIBITORS</i>	55
Small Molecule Inhibitors	55
<i>TABLE 37 ATP COMPETITIVE AND NON-COMPETITIVE INHIBITORS</i>	55
Antibody (Monoclonal) Inhibitors	55
CLASSIFICATION BY TYPES OF AMINO ACID PHOSPHORYLATION	56
SERINE/THREONINE KINASE INHIBITORS	56
<i>TABLE 38 TYPES OF SERINE/THREONINE KINASE INHIBITORS</i>	56
TYROSINE KINASE INHIBITORS	57
Receptor Tyrosine Kinase (RTK) Inhibitors	57
<i>TABLE 39 TYPES OF RECEPTOR TYROSINE KINASE INHIBITORS</i>	58
Non-Receptor Tyrosine Kinase (NRTK) Inhibitors	58
<i>TABLE 40 TYPES OF NON-RECEPTOR TYROSINE KINASE INHIBITORS</i>	58
CLASSIFICATION BY SITE OF ACTION	59
<i>TABLE 41 CLASSIFICATION OF KINASE INHIBITORS BY SITE OF ACTION</i>	59
CHAPTER 5 DRUG DISCOVERY TECHNOLOGIES (REPORT BIO020D)	61
STUDY GOALS AND OBJECTIVES	61
REASONS FOR DOING THIS STUDY	61
SCOPE AND FORMAT	61
METHODOLOGY AND INFORMATION SOURCES	62
INTENDED AUDIENCE	62
ANALYST CREDENTIALS	62
RELATED REPORTS	62
SUMMARY	62
<i>TABLE 42 GLOBAL MARKET FOR DRUG DISCOVERY TECHNOLOGIES AND PRODUCTS, THROUGH 2017 (\$ BILLIONS)</i>	63

TOPIC	PAGE NO.
<i>FIGURE 4 GLOBAL MARKET FOR DRUG DISCOVERY TECHNOLOGIES AND PRODUCTS, 2011-2017 (\$ BILLIONS)</i>	64
INTRODUCTION	64
PRECLINICAL TESTING AND SUBMISSION OF AN INVESTIGATIONAL NEW DRUG	66
CLINICAL TRIALS	67
SUBMISSION OF NEW DRUG APPLICATION OR BIOLOGICAL LICENSING APPLICATION	67
POST-FOOD AND DRUG ADMINISTRATION APPROVAL	68
IMPACT OF GOVERNMENT REGULATIONS AND REGULATORY APPROVALS ON THE DRUG DISCOVERY INDUSTRY	68
NEW DRUG APPROVALS	68
<i>TABLE 43 NEW MOLECULAR ENTITY (NME) APPLICATIONS VERSUS APPROVAL BY THE FDA, 2006-2010</i>	69
<i>FIGURE 5 NEW MOLECULAR ENTITY (NME) APPLICATIONS VERSUS APPROVAL BY THE FDA, 2006-2010</i>	69
TIMELINE AND COSTS	70
<i>FIGURE 6 TIMELINE FOR DRUG DEVELOPMENT PROCESS</i>	70
<i>TABLE 44 FACTS ABOUT DRUG DISCOVERY AND DEVELOPMENT FOR 2010</i>	71
<i>TABLE 45 R&D SPENDING FOR DRUG DISCOVERY IN BIOPHARMACEUTICAL COMPANIES, 2008-2012 (\$ MILLIONS)</i>	71
IMPORTANCE OF TECHNOLOGY IN DRUG DISCOVERY	72
MARKET LANDSCAPE IN THE DRUG DISCOVERY SECTOR	73
<i>TABLE 46 FDA-APPROVED DRUGS FOR SALE IN THE U.S., 2001-2011</i>	73
<i>TABLE 47 GLOBAL PHARMACEUTICAL MARKET VALUE, THROUGH 2017 (\$ BILLIONS)</i>	74
MARKET PARTICIPANTS IN THE DRUG DISCOVERY SECTOR	74
<i>TABLE 48 TOP GLOBAL PHARMACEUTICAL CORPORATION RANKING, 2009</i>	75
<i>TABLE 49 NUMBER OF DEALS AND THEIR VALUE IN THE PHARMACEUTICAL INDUSTRY IN DIFFERENT COUNTRIES, 2010</i>	76
PATENTS AND DRUG DISCOVERY TECHNOLOGY	76
<i>TABLE 50 PATENT APPLICATIONS IN DRUG DISCOVERY FROM MARCH 2012</i>	78
CHAPTER 6 ANTIBODY DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (REPORT BIO016H)	82
STUDY GOALS AND OBJECTIVES	82
REASONS FOR DOING THE STUDY	82
INTENDED AUDIENCE	82
SCOPE OF REPORT	83
INFORMATION SOURCES	83
ANALYST CREDENTIALS	83
RELATED REPORTS	84
SUMMARY	84
<i>TABLE 51 GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, THROUGH 2016 (\$ MILLIONS)</i>	84
<i>FIGURE 7 GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, 2009-2016 (\$ MILLIONS)</i>	84
OVERVIEW	85
DEFINITIONS	85
THE IMPORTANCE OF ANTIBODY DRUGS AND DIAGNOSTICS	87
INTELLECTUAL PROPERTY ISSUES AND PATENT LICENSING	88
THE HISTORY OF THE COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS	88

TOPIC	PAGE NO.
<i>TABLE 52 TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS</i>	88
ADVANTAGES OF MONOCLONAL ANTIBODY DRUGS	89
WHY DO MONOCLONAL ANTIBODY PRODUCTS HAVE SO MANY APPLICATIONS COMPARED WITH POLYCLONAL ANTIBODY PRODUCTS?	90
VALUATION OF ANTIBODY PRODUCT SALES	90
TECHNOLOGY AND TECHNICAL ISSUES	91
<i>TABLE 53 MONOCLONAL ANTIBODIES VERSUS SMALL MOLECULE DRUGS</i>	93
<i>TABLE 54 MONOCLONAL ANTIBODIES VERSUS POLYCLONAL ANTIBODIES</i>	94
THE HAMA PROBLEM AND ITS RESOLUTION	94
PHAGE DISPLAY AND POLYSOME DISPLAY	95
DIRECTED EVOLUTION	97
ANTIBODY CLASSES	97
<i>TABLE 55 ANTIBODY TYPES AND DESCRIPTIONS</i>	97
ANTIBODY FORMS IN PRODUCTS	98
<i>TABLE 56 GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES BY ANTIBODY TECHNOLOGY TYPE, THROUGH 2016 (\$ MILLIONS)</i>	98
<i>TABLE 57 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY ANTIBODY FORM (NUMBER/%)</i>	99
<i>TABLE 58 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY TECHNOLOGY FORM AND STAGE OF DEVELOPMENT</i>	99
<i>TABLE 59 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY TARGET</i>	99
CHAPTER 7 GLOBAL MARKETS FOR MEDIA, SERA AND REAGENTS IN BIOTECHNOLOGY (REPORT BIO014G)	102
STUDY OBJECTIVES	102
REASONS FOR DOING THIS STUDY	102
INTENDED AUDIENCE	102
SCOPE OF THE STUDY	102
METHODOLOGY	103
INFORMATION SOURCES	103
ANALYST CREDENTIALS	103
RELATED BCC RESEARCH REPORTS	103
PHAGE DISPLAY AND POLYSOME DISPLAY	104
<i>TABLE 60 GLOBAL REVENUES FROM MEDIA, SERA AND REAGENTS USED IN THE BIOTECHNOLOGY MARKET, THROUGH 2016 (\$ MILLIONS)</i>	105
<i>FIGURE 8 GLOBAL REVENUES FROM MEDIA, SERA AND REAGENTS USED IN THE BIOTECHNOLOGY MARKET, 2009-2016 (\$ MILLIONS)</i>	105
OVERVIEW	106
DEFINITIONS	106
HISTORY	106
<i>TABLE 61 HISTORICAL EVENTS IN CELL CULTURE DEVELOPMENT</i>	106
TYPES OF CELL CULTURES	108
PRIMARY CULTURES	108
<i>TABLE 62 ADVANTAGES AND DISADVANTAGES OF PRIMARY CELL CULTURE</i>	108
SECONDARY CELL CULTURE	108
CONTINUOUS CELL CULTURE	109
<i>TABLE 63 ADVANTAGES AND DISADVANTAGES OF CONTINUOUS CELL CULTURE</i>	109
MORPHOLOGY OF CELLS IN CULTURE	109
FIBROBLASTIC CELLS	109

TOPIC	PAGE NO.
EPITHELIAL-LIKE CELLS	109
LYMPHOBLAST-LIKE CELLS	109
BASIC SYSTEMS FOR CELL CULTURE	109
<i>TABLE 64 ADHERENT CULTURE VS. SUSPENSION CULTURE</i>	110
CELL LINE, CELL STRAIN AND TRANSFORMED CELL LINES	110
CHARACTERISTICS OF IMMORTALIZED CELL LINES	110
FACTORS AFFECTING CELL CULTURE	111
APPLICATIONS OF CELL CULTURE	111
MODEL SYSTEM	111
CANCER RESEARCH	111
VIROLOGY	112
<i>TABLE 65 CULTURE MEDIA USED FOR THE PRODUCTION OF VACCINES</i>	112
GENETICALLY ENGINEERED PROTEINS	113
<i>TABLE 66 POTENTIAL SOURCES OF CELL CULTURE ADDITIVES</i>	114
Recombinant Thrombolytic Agents	115
<i>TABLE 67 RECOMBINANT THROMBOLYTIC AGENTS</i>	115
Recombinant Coagulation Factor	115
<i>TABLE 68 RECOMBINANT COAGULATION FACTOR</i>	116
Cytokines	116
Hematopoietic Growth Factors	117
Human Growth Hormones	117
Monoclonal Antibodies	117
TISSUE AND ORGAN REPLACEMENT	118
CHAPTER 8 DNA SEQUENCING: EMERGING TECHNOLOGIES AND APPLICATIONS (REPORT BIO045D)	120
STUDY GOALS AND OBJECTIVES	120
REASONS FOR DOING THE STUDY	120
INTENDED AUDIENCE	121
SCOPE AND FORMAT	121
METHODOLOGY	121
INFORMATION SOURCES	122
RELATED BCC REPORTS	122
ANALYST CREDENTIALS	122
EXECUTIVE SUMMARY	122
<i>TABLE 69 GLOBAL VALUE OF SEQUENCING PRODUCTS AND SERVICES BY TYPE, THROUGH 2016 (\$ MILLIONS)</i>	123
<i>FIGURE 9 GLOBAL VALUE OF SEQUENCING PRODUCTS AND SERVICES BY TYPE, 2010-2016 (\$ MILLIONS)</i>	123
INTRODUCTION	124
<i>TABLE 70 SCOPE OF THIS REPORT</i>	125
SEQUENCING INDUSTRY MARKET	125
<i>TABLE 71 GLOBAL VALUE OF THE SEQUENCING MARKET BY PRODUCT TYPE, THROUGH 2016 (\$ MILLIONS)</i>	126
SEQUENCING INDUSTRY GROWTH DRIVING FORCES	126
<i>TABLE 72 KEY GROWTH DRIVING FORCES IN THE DNA SEQUENCING MARKET</i>	126
SEQUENCING PRODUCTS	127
SEQUENCING INSTRUMENTS AND CONSUMABLES	127

TOPIC	PAGE NO.
SAMPLE PREPARATION REAGENTS AND KITS	128
BIOINFORMATICS	128
SEQUENCING SERVICES	128
SEQUENCING PRODUCT LIFE CYCLE STATUS	128
<i>TABLE 73 LIFE CYCLE OF DNA SEQUENCING TECHNOLOGIES</i>	129
SEQUENCING INDUSTRY	129
<i>TABLE 74 SEQUENCING INSTRUMENT COMPETITORS BY TECHNOLOGY</i>	129

LIST OF TABLES

TABLE HEADING	PAGE NO.
TABLE 1 GLOBAL VALUE OF AGRICULTURAL BIOTECHNOLOGY MARKET, BY MARKET SEGMENT, THROUGH 2017 (\$ MILLIONS)	6
TABLE 2 SCOPE OF THIS REPORT	7
TABLE 3 GLOBAL VALUE OF AGRICULTURAL BIOTECHNOLOGY MARKET BY MARKET SEGMENT, THROUGH 2017 (\$ MILLIONS)	8
TABLE 4 AGRICULTURAL BIOTECHNOLOGY MARKET DRIVING FORCES	9
TABLE 5 LIFE CYCLE STATUS OF AGRICULTURAL BIOTECHNOLOGIES	10
TABLE 6 IMPACT OF NEW TECHNOLOGIES ON CROP PRODUCTIVITY, 1860-PRESENT	11
TABLE 7 AGRICULTURAL BIOTECHNOLOGY INDUSTRY KEY STRUCTURAL COMPONENTS	11
TABLE 8 DNA SEQUENCING TECHNOLOGY	12
TABLE 9 DNA SEQUENCING TECHNOLOGY IN AGRICULTURAL BIOTECHNOLOGY	13
TABLE 10 COMPARISON OF GENETIC ENGINEERING AND SYNTHETIC BIOLOGY	14
TABLE 11 GENETIC ENGINEERING/SYNTHETIC BIOLOGY TECHNOLOGY IN AGRICULTURAL BIOTECHNOLOGY	15
TABLE 12 BIOCHIPS TECHNOLOGIES	16
TABLE 13 BIOCHIPS TECHNOLOGIES IN AGRICULTURAL BIOTECHNOLOGY	16
TABLE 14 RNA INTERFERENCE TECHNOLOGY	17
TABLE 15 RNA INTERFERENCE AGRICULTURAL TECHNOLOGIES	18
TABLE 16 PLANT TECHNOLOGIES	18
TABLE 17 GENETICALLY MODIFIED SEED DEVELOPMENT PROCESS	19
TABLE 18 SEED PRODUCTION, STORAGE AND ENHANCEMENT TECHNOLOGIES	20
TABLE 19 GLOBAL DEMAND FOR BIOSIMILARS BY VALUE, THROUGH 2016 (\$ MILLIONS)	26
TABLE 20 SIMILAR BIOLOGICAL PRODUCTS: TERMINOLOGIES AND THEIR DEFINITIONS AS USED BY VARIOUS REGULATORY AGENCIES	29
TABLE 21 BIOSIMILARS VERSUS SMALL MOLECULE GENERICS	32
TABLE 22 GLOBAL REVENUES OF LEADING BIOPHARMACEUTICALS	34
TABLE 23 BIOLOGIC DRUGS LOSING PATENT PROTECTION BETWEEN 2012 AND 2017	34
TABLE 24 POPULAR REFERENCE PRODUCTS TARGETED BY KEY PLAYERS	35
TABLE 25 ANNUAL COSTS FOR THE TREATMENT USING SOME OF THE BIOLOGIC DRUGS	35
TABLE 26 COST COMPARISON FOR RENAL DISEASE-ASSOCIATED ANEMIA TREATMENT IN EUROPE	36
TABLE 27 BIOSIMILARS APPROVED BY EMA, 2011	37
TABLE 28 BIOSIMILARS APPROVED IN OTHER REGULATED MARKETS: AUSTRALIA, CANADA, JAPAN AND THE U.S.	38
TABLE 29 TOP PLAYERS IN THE GLOBAL BIOSIMILAR MARKET	39
TABLE 30 THE GLOBAL AND REGIONAL BIOSIMILAR MARKETS BY VALUE, THROUGH 2016 (\$ MILLIONS)	40
TABLE 31 THE GLOBAL MARKETS FOR VARIOUS PRODUCT CLASSES OF BIOSIMILARS BY VALUE, THROUGH 2016 (\$ MILLIONS)	41
TABLE 32 SCIENTIFIC AND REGULATORY CONCERNS RELATED TO BIOSIMILAR AUTHORIZATION	43
TABLE 33 GLOBAL REVENUE OF KINASE INHIBITORS MARKET, THROUGH 2016 (\$ MILLIONS)	49
TABLE 34 CLASSIFICATION OF ENZYME INHIBITORS	52
TABLE 35 HISTORY OF PROTEIN KINASES	54
TABLE 36 TYPES OF KINASE INHIBITORS	55
TABLE 37 ATP COMPETITIVE AND NON-COMPETITIVE INHIBITORS	55
TABLE 38 TYPES OF SERINE/THREONINE KINASE INHIBITORS	56
TABLE 39 TYPES OF RECEPTOR TYROSINE KINASE INHIBITORS	58

TABLE HEADING	PAGE NO.
TABLE 40 TYPES OF NON-RECEPTOR TYROSINE KINASE INHIBITORS	58
TABLE 41 CLASSIFICATION OF KINASE INHIBITORS BY SITE OF ACTION	59
TABLE 42 GLOBAL MARKET FOR DRUG DISCOVERY TECHNOLOGIES AND PRODUCTS, THROUGH 2017 (\$ BILLIONS)	63
TABLE 43 NEW MOLECULAR ENTITY (NME) APPLICATIONS VERSUS APPROVAL BY THE FDA, 2006-2010	69
TABLE 44 FACTS ABOUT DRUG DISCOVERY AND DEVELOPMENT FOR 2010	71
TABLE 45 R&D SPENDING FOR DRUG DISCOVERY IN BIOPHARMACEUTICAL COMPANIES, 2008-2012 (\$ MILLIONS)	71
TABLE 46 FDA-APPROVED DRUGS FOR SALE IN THE U.S., 2001-2011	73
TABLE 47 GLOBAL PHARMACEUTICAL MARKET VALUE, THROUGH 2017 (\$ BILLIONS)	74
TABLE 48 TOP GLOBAL PHARMACEUTICAL CORPORATION RANKING, 2009	75
TABLE 49 NUMBER OF DEALS AND THEIR VALUE IN THE PHARMACEUTICAL INDUSTRY IN DIFFERENT COUNTRIES, 2010	76
TABLE 50 PATENT APPLICATIONS IN DRUG DISCOVERY FROM MARCH 2012	78
TABLE 51 GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, THROUGH 2016 (\$ MILLIONS)	84
TABLE 52 TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS	88
TABLE 53 MONOCLONAL ANTIBODIES VERSUS SMALL MOLECULE DRUGS	93
TABLE 54 MONOCLONAL ANTIBODIES VERSUS POLYCLONAL ANTIBODIES	94
TABLE 55 ANTIBODY TYPES AND DESCRIPTIONS	97
TABLE 56 GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES BY ANTIBODY TECHNOLOGY TYPE, THROUGH 2016 (\$ MILLIONS)	98
TABLE 57 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY ANTIBODY FORM (NUMBER/%)	99
TABLE 58 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY TECHNOLOGY FORM AND STAGE OF DEVELOPMENT	99
TABLE 59 ANTIBODIES IN CLINICAL STAGE DEVELOPMENT BY TARGET	99
TABLE 60 GLOBAL REVENUES FROM MEDIA, SERA AND REAGENTS USED IN THE BIOTECHNOLOGY MARKET, THROUGH 2016 (\$ MILLIONS)	105
TABLE 61 HISTORICAL EVENTS IN CELL CULTURE DEVELOPMENT	106
TABLE 62 ADVANTAGES AND DISADVANTAGES OF PRIMARY CELL CULTURE	108
TABLE 63 ADVANTAGES AND DISADVANTAGES OF CONTINUOUS CELL CULTURE	109
TABLE 64 ADHERENT CULTURE VS. SUSPENSION CULTURE	110
TABLE 65 CULTURE MEDIA USED FOR THE PRODUCTION OF VACCINES	112
TABLE 66 POTENTIAL SOURCES OF CELL CULTURE ADDITIVES	114
TABLE 67 RECOMBINANT THROMBOLYTIC AGENTS	115
TABLE 68 RECOMBINANT COAGULATION FACTOR	116
TABLE 69 GLOBAL VALUE OF SEQUENCING PRODUCTS AND SERVICES BY TYPE, THROUGH 2016 (\$ MILLIONS)	123
TABLE 70 SCOPE OF THIS REPORT	125
TABLE 71 GLOBAL VALUE OF THE SEQUENCING MARKET BY PRODUCT TYPE, THROUGH 2016 (\$ MILLIONS)	126
TABLE 72 KEY GROWTH DRIVING FORCES IN THE DNA SEQUENCING MARKET	126
TABLE 73 LIFE CYCLE OF DNA SEQUENCING TECHNOLOGIES	129
TABLE 74 SEQUENCING INSTRUMENT COMPETITORS BY TECHNOLOGY	129

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
FIGURE 1 GLOBAL VALUE OF AGRICULTURAL BIOTECHNOLOGY MARKET BY MARKET SEGMENT, 2011-2017 (\$ MILLIONS)	6
FIGURE 2 GLOBAL BIOSIMILAR DEMAND BY VALUE AND PRODUCT TYPE, 2011 (%)	26
FIGURE 3 GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016 (\$ MILLIONS)	49
FIGURE 4 GLOBAL MARKET FOR DRUG DISCOVERY TECHNOLOGIES AND PRODUCTS, 2011-2017 (\$ BILLIONS)	64
FIGURE 5 NEW MOLECULAR ENTITY (NME) APPLICATIONS VERSUS APPROVAL BY THE FDA, 2006-2010	69
FIGURE 6 TIMELINE FOR DRUG DEVELOPMENT PROCESS	70
FIGURE 7 GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, 2009-2016 (\$ MILLIONS)	84
FIGURE 8 GLOBAL REVENUES FROM MEDIA, SERA AND REAGENTS USED IN THE BIOTECHNOLOGY MARKET, 2009-2016 (\$ MILLIONS)	105
FIGURE 9 GLOBAL VALUE OF SEQUENCING PRODUCTS AND SERVICES BY TYPE, 2010-2016 (\$ MILLIONS)	123